Any Know-How and all other scientific, clinical, regulatory, marketing, financial and commercial information or data, whether communicated in writing, verbally or electronically, of the Prostate Cancer Sublicensee that is disclosed to or received by Merck pursuant to the Agreement or this Amendment shall be considered Proprietary Information of Licensee for purposes of the Agreement, and shall be subject to the provisions of Article IX of the Agreement.